Ishita Drugs & Industries share news, announcements and annual reports
BSE: 524400Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹73.80.
30 Oct: open ₹73.50, high ₹73.50, low ₹73.30
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹22 Cr4,064th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 31.03
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,350
Ishita Drugs & Industries share news and announcements
527 announcements, routine notices left out, newest first. Page 4 of 11.
Apr 2023
Feb 2023
14 Feb · Board meeting
7 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Nov 2022
19 Nov · Non-Applicability Of Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
17 Nov · Board meeting
14 Nov · Board meeting
7 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
17 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 017 Oct · Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
1 Oct · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Sep 2022
12 Sep · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Aug 2022
31 Aug · INTIMATION OF E- VOTING AS PER THE REGULATION 44 OF SEBI (LODR) REGULATION, 2015
13 Aug · Board meeting
8 Aug · Board meeting
Meeting on 13 Aug 2022: quarterly results
Jul 2022
15 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2022
9 Jun · Non-Applicability Of Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
6 Jun · Revised Certificate File Under Reg.40 (9) & Reg.40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Year Ended March 31, 2022
May 2022
24 May · Board meeting
Meeting on 30 May 2022: increase in authorised capital and audited results6 May · Legal
Exchange has sought clarification from Ishita Drugs & Industries Ltd on May 5, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Apr 2022
18 Apr · Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On 31St March, 2022.
13 Apr · Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
12 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Mar 2022
Feb 2022
14 Feb · Board meeting
7 Feb · Board meeting
Meeting on 14 Feb 2022: quarterly results
Jan 2022
20 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....12 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0